Form 4: AstraZeneca Executive Acquires Shares

Mani Sharma, SVP of AstraZeneca, acquired ordinary shares under the company's Share Incentive Plan.

Summary

• Mani Sharma, SVP, Group Controller and Head of Global Finance Services at AstraZeneca PLC, acquired 19,263.4659 ordinary shares.
• The acquisition occurred on June 8, 2026, under the Issuer's Share Incentive Plan.
• The purchase price was $179.75 per share, reflecting a conversion from GBP 134.54 at a rate of GBP 1.0000 to $1.3360 on June 5, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine share acquisition by an executive under an existing plan, rather than a significant strategic event or financial performance indicator.

Positives

• Executive participation in the Share Incentive Plan indicates confidence in the company's future performance.
• Acquisition of shares by a senior finance executive can be seen as a positive signal to the market.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings, such as this one from AstraZeneca, are standard disclosures for insider transactions. They provide transparency into the holdings and activities of company executives and directors, which is a common practice across the pharmaceutical and biotechnology industry.

Stakeholder Impact

• Shareholders: Increased transparency into executive share ownership, potentially signaling confidence in the company.
• Employees: Reinforces the existence and operation of the Share Incentive Plan.

Key Dates

Keywords

AstraZeneca, Form 4, Insider Trading, Share Incentive Plan, Stock Acquisition, SEC Filing, Mani Sharma